1. Home
  2. LEGN vs MASI Comparison

LEGN vs MASI Comparison

Compare LEGN & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • MASI
  • Stock Information
  • Founded
  • LEGN 2014
  • MASI 1989
  • Country
  • LEGN United States
  • MASI United States
  • Employees
  • LEGN N/A
  • MASI N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • MASI Medical/Dental Instruments
  • Sector
  • LEGN Health Care
  • MASI Health Care
  • Exchange
  • LEGN Nasdaq
  • MASI Nasdaq
  • Market Cap
  • LEGN 6.7B
  • MASI 8.1B
  • IPO Year
  • LEGN 2020
  • MASI 2007
  • Fundamental
  • Price
  • LEGN $33.88
  • MASI $141.30
  • Analyst Decision
  • LEGN Strong Buy
  • MASI Buy
  • Analyst Count
  • LEGN 12
  • MASI 6
  • Target Price
  • LEGN $73.36
  • MASI $194.60
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • MASI 608.9K
  • Earning Date
  • LEGN 11-11-2025
  • MASI 11-04-2025
  • Dividend Yield
  • LEGN N/A
  • MASI N/A
  • EPS Growth
  • LEGN N/A
  • MASI N/A
  • EPS
  • LEGN N/A
  • MASI N/A
  • Revenue
  • LEGN $796,838,000.00
  • MASI $2,153,800,000.00
  • Revenue This Year
  • LEGN $70.75
  • MASI N/A
  • Revenue Next Year
  • LEGN $52.47
  • MASI $7.80
  • P/E Ratio
  • LEGN N/A
  • MASI N/A
  • Revenue Growth
  • LEGN 74.75
  • MASI 25.86
  • 52 Week Low
  • LEGN $27.34
  • MASI $111.03
  • 52 Week High
  • LEGN $52.15
  • MASI $194.88
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 46.85
  • MASI 41.04
  • Support Level
  • LEGN $32.70
  • MASI $140.11
  • Resistance Level
  • LEGN $34.71
  • MASI $148.95
  • Average True Range (ATR)
  • LEGN 1.24
  • MASI 3.92
  • MACD
  • LEGN 0.13
  • MASI 0.23
  • Stochastic Oscillator
  • LEGN 54.82
  • MASI 40.25

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About MASI Masimo Corporation

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Share on Social Networks: